Celgene Corporation (CELG): Still Revving Up With Revlimid

Page 2 of 2

More good news could be on the way, also. Celgene submitted for regulatory approval in 2012 for Revlimid in treating mantle cell lymphoma. Four late-stage clinical trials are under way, studying the effects of Revlimid in the treatment of newly diagnosed multiple myeloma.

Look for Revlimid to continue as a powerhouse for Celgene. At the same time, though, the drug will shrink as a percentage of total revenue as more products step up to the plate. Stay tuned over the next few weeks as we dig into these up-and-comers from this biotech on the move.

The article Still Revving Up With Revlimid originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2